Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Stuart M. Grant Buys 1,515,151 Shares

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant acquired 1,515,151 shares of the stock in a transaction dated Tuesday, July 2nd. The stock was acquired at an average cost of $0.66 per share, with a total value of $999,999.66. Following the transaction, the insider now directly owns 10,914,153 shares in the company, valued at $7,203,340.98. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Eyenovia Stock Up 3.4 %

NASDAQ:EYEN opened at $0.77 on Thursday. The company has a current ratio of 0.88, a quick ratio of 0.66 and a debt-to-equity ratio of 3.72. Eyenovia, Inc. has a twelve month low of $0.50 and a twelve month high of $2.60. The company has a market cap of $41.39 million, a PE ratio of -1.02 and a beta of 1.78. The company’s 50 day moving average is $0.74 and its two-hundred day moving average is $1.24.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.23 million. Analysts anticipate that Eyenovia, Inc. will post -0.56 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Thursday, May 16th.

Institutional Trading of Eyenovia

Several large investors have recently added to or reduced their stakes in the company. Armistice Capital LLC raised its stake in shares of Eyenovia by 41.8% in the fourth quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock worth $9,106,000 after purchasing an additional 1,290,979 shares during the last quarter. Vanguard Group Inc. lifted its stake in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after acquiring an additional 360,924 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Eyenovia by 1,444.4% in the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after acquiring an additional 205,390 shares during the period. PFG Investments LLC purchased a new position in shares of Eyenovia during the first quarter worth $69,000. Finally, Nations Financial Group Inc. IA ADV purchased a new stake in Eyenovia in the fourth quarter valued at $84,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.